first antiandrogen discovered antiandrogens antagonise androgen receptor ar thereby block biological effects testosterone dihydrotestosterone dht antiandrogens important men hormonally responsive diseases like prostate cancer benign prostatic hyperplasia bhp acne seborrhea hirsutism androgen alopecia antiandrogens mainly used treatment prostate research suggests ars could linked disease progression triplenegative breast cancer salivary duct antiandrogens potentially used treat antiandrogens small molecules either steroidal nonsteroidal depending ligand chemistry steroidal antiandrogens share similar steroid structure nonsteroidal antiandrogens nsaas may structurally distinctive pharmacophores limited number compounds available clinical use despite fact large variety antiandrogen compounds discovered beginning twentieth century relationship pituitary testes prostate gland established american physician charles brenton huggins found castration estrogen administration led glandular atrophy men could reversed readministration androgen huggins treated prostate cancer patients androgen ablation either castration estrogen therapy beneficial effect androgen ablation metastatic prostate cancer realised awarded nobel prize physiology medicine became evident androgen ablation alone insuffient cure patients advanced prostate cancer late androgen receptor ar discovered characterized screening chemical libraries ar blockers led discovery first antiandrogen cyproterone acetate group added cyproterone created cyproterone acetate antiandrogen flutamide discovered united states food drug administration fda approved use treatment prostate cancer bicalutamide approved nilutamide followed year ar belongs steroid receptor subfamily nuclear receptor superfamily function regulated binding androgens initiates sequential conformation changes receptor affects receptorprotein receptordna interactions endogenous androgens mainly testosterone ar expressed cells wide range tissues throughout entire body beyond primary secondary sexual ar gene long codes protein amino acids one ar gene identified humans located chromosome x comprises four main regions see figure two functions identified ar critical roles regulation target gene transactivation nterminal activation function cterminal activation function ligandindependent plays primary role target gene transactivation liganddependent shows limited unbound ar mainly located cytoplasm like typical steroid receptor associated complex heat shock proteins hsp interactions lbd androgens either agonists antagonists position ligandbinding pocket lbp cytosolic ar bind lbd see figure ar goes series conformational changes hsp dissociate ar transformed ar undergoes dimerisation phosphorylation translocates nucleus translocated receptor binds androgenresponse elements promoter androgen responsive gene consensus sequence located either upstream downstream transcription start site tss ar target genes recruitment transcription cofactors including coactivators corepressors general transcriptional machinery ensures transactivation arregulated gene expression complicated processes initiated ligandinduced conformational changes lbd ligand specific recruitment coregulators might crucial agonist antagonist activity ar ligands binding dna also required arregulated gene expression also known classic genomic gene function cyproterone steroidal antiandrogen competitively inhibits binding testosterone dht ar cyproterone binds ars expressed prostate cancer cells well ar expressed hypothalamus pituitary therefore cyproterone blocks negative feedback androgens hypothalamicpituitary level leading increased luteinizing hormone lh serum levels rise lh levels causes increase serum testosterone levels ultimately diminishes ability cyproterone compete ar binding block androgenic cyproterone acetate developed overcome problem formed adding acetate group cyproterone see figure cyproterone acetate dual mode action competes directly dht binding ar also inhibits gonadotropin secretion thereby reduces androgen estrogen lh cyproterone acetate acts directly antiandrogen prostate cancer cells also functions indirectly decrease serum testosterone levels latter causes limitations cyproterone acetate central effects androgen secretion subsequent loss libido sexual potency several reports also state cyproterone acetate causes liver hyperplasia side effects gave pharmaceutical companies incentive search alternative pure nsaas would side pure antiandrogens block androgen receptor without exerting agonistic hormonal flutamide became first nsaa tested clinically later nsaas bicalutamide nilutamide developed alleged advantages compounds affect libido potency like centrally acting compounds development luteinizinghormonereleasing hormone lhrh agonists cyproterone acetate theory prove true nsaas eventually crossed barrier like cyproterone acetate leading subsequent increase serum testosterone flutamide arylpropionamide analog pure antiandrogenic properties seen figure completely absorbed gastrointestinal tract oral administration undergoes extensive first pass metabolism active form hydrolysis product hydroxyflutamide potent ar antagonist flutamide vivo higher binding affinity ar hydroxyflutamide elimination halflife hours humans hydrolysis amide bond represents major metabolic pathway active metabolite reversing stimulatory effect dht ventral prostate weight flutamide approximately potent cyproterone acetate hydroxyflutamide relatively low binding affinity ar therefore generally used high doses order achieve complete ar blockage nilutamide nitroaromatic hydantoin analog flutamide seen figure nilutamide eliminated exclusively metabolism mainly reduction aromatic nitro group although hydrolysis one carbonyl functions imidazolinedione identified much less susceptible hepatic metabolism amide bond hydroxuflutamide results longer halflife nilutamide humans days nevertheless nitro anionfree radical formed nitro reduction could still associated hepatotoxicity humans especially using relatively high dosage employed androgen nilutamide causes sideeffects limit usage pneumonitis delayed adaption bicalutamide arylpropionamide analog seen figure replaced flutamide nilutamide first choice antiandrogen prostate cancer treatment bicalutamide hepatotoxic flutamide nilutamide longer halflife days humans allows day administration lower dosage bicalutamide shares amide bond structure flutamide even amide bond hydrolysis discovered rats humans could explain prolonged half life bicalutamide bicalutamide cyano group para position instead nitro group like flutamide nilutamide change groups avoids nitro reduction observed nilutamide bicalutamide chiral carbon structure labeled asterisk figure connected hydroxyl methyl groups therefore administered postapproval investigation revealed antiandrogenic activity resides almost entirely renantiomer rbicalutamide almost fourfold higher affinity prostate ar hydroxyflutamide better sideeffect profile compared cyproterone acetate derivative shows major antiandrogenic activity together androgenic activities cyproterone acetate displays high affinity ar rats increases group removed compound chlorine atom replaced methyl group binding slightly decreases whereas removal double bond modifies binding kinetics see figure hydroxyflutamide analogues bicalutamide nilutamide share anilide ring structure structures seen figure anilide ring coloured red three compounds require electrondeficient aromatic ring efficient ar binding replacing anilide alkene gives weakly active compounds attributed lack intramolecular hydrogen binding poor hydrogenbond donor various combinations electronwithdrawing substitutions aniline ring drugs shown higher binding ar receptor compared compounds chloro trifluoromethyl group meta position either cyano nitrogen group para position hydroxyflutamide group compounds differed aromatic ring bind ar suggests bisubstitution hydroxyflutamide ring essential high ar binding affinity also demonstrated hydroxyflutamide requires strong hydrogen bond donor ability tertiary hydroxyl group fixed conformers involved intramolecular hydrogen binding bind effectively bicalutamide antiandrogenic activities sulfide sulfone substitutions xlinkage tested vitro sulfides showed cases least higher binding affinity corresponding sulfones however relationship reversed group binding affinity sulfone higher sulfide results indicate substituents bring largely determine effect xlinkage ar binding researchers proposed tertiary hydroxyl group involved direct interaction ar acetyl group introduced hydroxyl moiety receptor binding affinity greatly nilutamide low affinity ar tested castrated rat prostate modifications replacing atom oxygen little effect affinity compound prostate ar replacing oxygen atom sulfur atom position imidazole ring adding butylalcohol atom receptor binding biological activity compound increases times nsaas also compound bind steroid receptors methyl group changed butylalcohol group compound shows times antiandrogenic activity vivo bicalutamide nilutamide antiandrogens currently market particularly useful treatment prostate cancer early stages however prostate cancer often progresses hormonerefractory state cancer progresses presence continued androgen ablation antiandrogen suggests long term use antiandrogens prostate cancer lead development androgenindependent prostate cancer cells ability adrenal androgens support tumor phenomenon called antiandrogen withdrawal syndrome aws one major drawbacks existing antiandrogens aws defined tumor regression symptomatic relief observed upon discontinuation antiandrogen therapy mechanism fully understood current theories include alterations ar gene coregulator proteins andor signal transduction pathways antiandrogen resistance may also linked relative weakness current antiandrogens affinity times lower dht ar may also explain compensatory ar overexpression often ar gene mutations lbd alter ligand specificity andor functional activity exist thought contribute conversion ar antagonists agonists explains paradoxical temporary improvement sometimes observed patients antiandrogen therapy mutations great effect antagonist activities current small molecule antiandrogens make less efficient blocking ar function via indirect modulation inside lbp recent studies circulating tumor cells suggest mutation frequency higher previously assumed based tumor mutations examples known ar lbd mutations lncap prostate cancer cell line expresses ar point mutation causes proliferation presence antiandrogens hydroxyflutamide cyproterone acetate mutation also discovered patients antiandrogen withdrawal syndrome treated another study bicalutamide treatment lncap cells resulted two lbd mutations causing bicalutamide acquire agonist activity mutant mutation generates additional space sulfonyllinked phenyl ring bicalutamide accommodated location missing indole ring nonmutant ar presence side chain probably forces bicalutamide protrude thus precluding active position ar receptor however hydroxyflutamide worked antagonist mutant concurs theory flutamide nilutamide antagonize ar mechanism passive antagonism modest size drugs may therefore effective secondline therapy refractory prostate cancer previously treated antagonists nterminal domain ntd ar proposed overcome limitations current antiandrogens regarding mutant ars directly blocking ar function protein surface outside lbp direct blockade thought provide efficient strategy avoid overcome abnormal ar action aws well allowing flexibility structural modification without space limitations rigid steroid receptors similarities gene sequences protein structures leading often functional crosstalk among steroid receptors one criteria ar ntd antagonists achieve high degree specificity ar though important realize ar specificity necessarily translate vivo since ntd antagonists may also interact protein targets ar activation requires formation functional activation function region ar lbd mediates interactions ar various transcription cofactors therefore research ntd ar antagonists focuses peptides may directly block ar lbd protein surface even bound mutant ar ntd antagonists would able block function via direct surface interaction regardless ligand research ntd antagonists usually carried affinity screening phage display libraries express random peptides containing various signature motifs ars seem distinct preference fxxlf type binding motifs f phenylalanine l leucine x amino acid residue whereas nuclear receptors highly similar binding mechanism lxxll type binding motifs provides unique opportunity development arspecific even though small molecule antagonists ntd antagonist targeting surface differ binding sites inhibit ar function disrupting function therefore mechanistically ntd antagonists may also classified antagonists functionally ar ntd plays primary role regulating target gene transcription activation mediating various receptorprotein intrareceptor nterminal cterminal interactions therefore modulation ntd function considered efficient strategy target ar action among various functional domains different nuclear receptors ntd least conserved could maybe become best target site ntd antagonists achieve ar specificity however structural features ntd undetermined due high degree flexibility conformation biochemical circular dichroism spectroscopy analysis suggest ar ntd highly disordered native conditions making difficult target drug reports chlorinated peptide sintokamide isolated marine sponges effectively inhibits ar nterminal domainactivated reporter gene transcription see figure evidence presented sufficient support conclusion sintokamide directly inhibits function ar ntd mechanism action needs small molecule antiandrogens available today undesirable side effects caused complete nonselective inhibition ar action minimize side effects new class tissue selective androgen receptor modulators sarms proposed novel approach treatment prostate cancer ligands behave antagonists prostate either activity agonist activity target tissues little effects anabolic tissues central nervous system cns however discovering new class ligands might challenging molecular mechanism ar action well several mechanisms proposed achieve tissue selectivity ar ligands definitive evidence exists role reductase reductase expressed specific tissues could therefore unique contributor tissue selectivity specific inhibition type enzyme finasteride blocks conversion testosterone dht several approaches might make use potential tissuespecific conversion develop sarms including development status small molecule antiandrogens undergoing research seen table atraric acid nbutylbenzenesulfonamide natural compounds antiandrogen properties purified bark african tree pygeum africanum see figures vitro assays shown selective ar agonists inhibit proliferation several prostate cancer cell lines atraric acid also hinders extracellular matrix invasion compounds able prevent androgeninduced nuclear translocation ar potent derivatives currently synthesized hope improving pharmacological profile two httpsenwikipediaorgwikidiscoveryanddevelopmentofantiandrogens